Background Teledermatology (TD) has emerged as a critical way of delivering care remotely in the COVID-19 pandemic. Objective We conducted a systematic review to assess how TD has been implemented worldwide. Methods We searched PubMed, SCOPUS, EMBASE, Web of Science and Google Scholar for articles on the use of TD for patient care, written in English and published from December 1 st 2019 to October 15 th 2020. Results 27 studies were included, involving 16,981 patients. There was significant uptake of TD during the pandemic. Synchronous TD appeared to be more commonly implemented than asynchronous TD. Common ambulatory dermatoses such as acne or eczema were reported to be more amenable to TD assessment and management. TD also appeared to be useful for the diagnosis of cutaneous involvement of COVID-19 infection and follow-up of stable onco-dermatology cases. Limitations Pooled analysis of all relevant outcomes was not always possible due to the heterogeneity in methodologies of included studies. Conclusions TD is a useful and convenient tool for the management of common ambulatory dermatoses in the COVID-19 pandemic.

No abstract

The characterization of cutaneous squamous cell carcinoma (cSCC) at the molecular level is lacking in the current literature due to the high mutational burden of this disease. Immunosuppressed patients afflicted with cSCC experience considerable morbidity and mortality. In this article, we review the molecular profile of cSCC among the immunosuppressed and immunocompetent populations at the genetic, epigenetic, transcriptomic, and proteometabolomic levels, as well as describing key differences in the tumor immune microenvironment between these two populations. We feature novel biomarkers from the recent literature which may serve as potential targets for therapy.